ArticleNanomaterials (Basel, Switzerland)2025
Multiplexed Integrin Detection and Cancer Cell Classification Using Multicolor Gap-Enhanced Gold Nanorods and Machine Learning Algorithm.
Article in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Integrins, cell-surface adhesion receptors involved in tumor progression, invasion, and metastasis, serve as crucial biomarkers for cancer diagnosis and therapeutic targeting. Multiplexed detection of integrins and cancer cell classification at the single-cell level allows for comprehensive profiling, facilitating precise identification and categorization of tumor cells that are heterogeneous in integrin expression and cell subtype. In this study, we developed a five-plex detection platform and demonstrated integrin profile for cancer cell classification leveraging surface-enhanced Raman scattering (SERS) with gap-enhanced gold nanorods (GENRs) in conjunction with advanced computational analysis. Specifically, we synthesized GENRs bearing five distinct Raman nanotags, each producing a unique spectral fingerprint upon targeting a specific integrin subtype expressed on cancer cell surfaces. SERS signals from single cancer cells-after labeling simultaneously with the five-color SERS nanotags-were collected on single cells and subsequently analyzed with classical least squares regression to reliably deconvolute and quantify expression level of five different integrin monomers. Utilizing a random forest classifier trained on integrin profiles from individual cancer cell lines, we achieved simultaneous detections of three different breast cancer cell lines, with exceptional classification accuracy of 99.9%. The feasibility of this method for multiplexed detection of circulating tumor cells was tested using peripheral blood mononuclear cells (PBMCs) spiked with mixed breast cancer cells from three cell lines. By integrating GENRs, multiplexed SERS nanotag technology, and machine learning, our platform significantly advances cancer diagnostics through accurate integrin-based cell profiling and classification. These findings highlight the potential of multiplexed integrin detection using SERS technology as a powerful diagnostic approach, ultimately supporting improved cancer subtype characterization, personalized diagnostics, and more targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.